Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

ss for the year ended June 30, 2011 compared to the net loss for the year ended June 30, 2010 was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca as a result of the successful completion of the research collaboration portion of the agreements.

RevenueRevenues in the quarter ended June 30, 2011 were $0.2 million, compared to $0.7 million for the same period in 2010.  For the year ended June 30, 2011, revenues were $1.5 million, compared to $14.2 million for year ended June 30, 2010.  

Costs and ExpensesFor the quarter ended June 30, 2011, total operating expenses were $4.7 million compared to $4.9 million for the comparable quarter of 2010.  For the year ended June 30, 2011, total operating expenses were $15.1 million compared to $17.2 million for the year ended June 30, 2010. The decreases in operating expenses for the respective periods is the result of reducing staffing levels pursuant to Palatin's strategic decision announced in September 2010.

Cash positionPalatin's cash and cash equivalents were $18.9 million as of June 30, 2011, compared to cash, cash equivalents and investments of $8.9 million at June 30, 2010, with current liabilities of $2.8 million as of June 30, 2011 compared to $2.4 million as of June 30, 2010.  

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST Palatin will host a conference call and webcast on September 22, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-800-281-7970 (domestic) or 1-913-312-0671 (international), pass code 9488233.  The webcas
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
(Date:12/19/2014)... With only 2 weeks left of ... Sartorius Biohit products . The product specials include Buy ... Pipette Trade-in Program, and free pipette tips. , Sartorius ... the world. They are ideal for lab technicians performing ... ,     Full volume range of 0.1 uL to ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... FT. LAUDERDALE, Fla., July 30 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials announced today that a ... provide eClinical solutions in connection with two of the CRO,s ... 700 subjects. Additional details were not disclosed. Phase IV studies ...
... , RALEIGH, N.C. , July 30 SmartGene, ... of genetic data, today announced that it has entered into an ... technology and integrated Web-based services to support more rapid and precise ... , Some bacteria and fungi do not grow quickly ...
... 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology ... based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... with its vaccine candidate for the Influenza A (H1N1) ... a single dose of 5 micrograms induced a positive ...
Cached Biology Technology:Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies 2SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 3
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... -- Look out, Indiana Jones. Dan Shain ... to frozen glaciers and the steamy Amazon planned, all ... cinematic icon, Shain, an associate professor of biology at ... returns home with treasure. He,s mined for ice ...
... Western Reserve University have developed a technique that has ... within hours, as opposed to the two days it ... mice, drug delivery time from injection to the cancer ... Using this as a model for potential human use, ...
... is a significant challenge for researchers. That challenge is prompting ... that data and to make it readily available. The ... Disease has created a new collaboration tool, WikiPathways to focus ... "Biological pathways connect genes and proteins in systems that ...
Cached Biology News:Rutgers biologist to study worms in Amazon, glaciers 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 3Gladstone scientists create Wikipathways to foster research collaboration 2
... This antibody is generated from rabbits immunized ... within aa 50~150 of human PLAU. Purified ... 0.09% (W/V) sodium azide. This antibody is ... eluted out with both high and low ...
... is a compact, lightweight, high current power supply ... 2500 milliamps. It is an excellent choice for ... It is also ideal for all types of ... set to automatically end a run and wil ...
... For use in Refrigerated Vapor Trap ... Vacuum Source (UVS) Models UVS400, UVS400A and ... polymer suitable for use for temperatures ranging ... has excellent thermal stability and does not ...
... proteomics demands the detection of very small ... the AXIMA-CFRplus with improved resolution (20,000) and ... increased confidence in protein identification. The AXIMA-CFRplus ... automated sample target handling and the ability ...
Biology Products: